Researchers say antiepilectic drug treatments administered when the brain is developing appear to trigger schizophrenia-like behavior in animal models.

PORTO, Portugal, December 8 /PRNewswire/ -- - Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate) Positive data from three phase III studies presented today at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM)(1) (eslicarbazepine acetate), a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures and has the potential to significantly improve quality of life and depressive symptoms in patients with partial refractory epilepsy, in combination with other anti-epileptic agents.(2),(3),(4) Zebinix(TM) is one of the proposed EU trade names for eslicarbazepine acetate. Zebinix(TM) 800mg and 1200mg once-daily significantly reduced the frequency of partial seizures by over one third during the 12 week maintenance period of the studies.(5),(6),(7),(8) In addition, new data presented for the first time at AES

By HELEN PUTTICK HEALTH CORRESPONDENT A SCOTTISH GP who prescribed sleeping tablets to a patient so she could end her life should be struck off, a panel of the General Medical Council was told yesterday.

By HELEN PUTTICK HEALTH CORRESPONDENT A GP who gave sleeping pills to an elderly patient so she could end her life was suspended for six months and may not return to his job.

A DOCTOR who admitted prescribing sleeping tablets to enable a pensioner to end her life has been branded irresponsible.